Nov 08, 2022 9:10am EST Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million
Jun 30, 2022 9:00am EDT Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
May 18, 2022 9:00am EDT Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
Feb 14, 2022 9:00am EST Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
Jan 04, 2022 9:00am EST Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
Dec 22, 2021 9:00am EST Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market